“A solid growth play is a name that appears poised to not only grow at an above-average rate but also reward investors handsomely over the long run,” notes the author of today’s article, who proceeds to highlight three “Buy-rated stocks flagged by the analysts for their strong long-term growth narratives. On top of this, each boasts substantial upside potential from the current share price.” For these three stocks – including a biopharmaceutical company focused on underserved patient communities – For more, CLICK HERE.
Each of the 11 stocks highlighted in today’s article outperformed the market this summer – having returned more than 10% during the 3-month period in which the S&P 500 gained about 5%. More importantly, each of these stocks appears to still have room to run – and potentially continue to generate outsize returns – as they are all still trading below analysts’ fair value estimates. To find out what these 11 stocks are – and which three analysts are most confident in – CLICK HERE.